REG - Reckitt Benckiser Gp - Commencement of Second Tranche of Share Buyback

Reckitt BenckiserAnnouncement

Wed 07:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2859Ea&default-theme=true

RNS Number : 2859E  Reckitt Benckiser Group PLC  22 October 2025

RECKITT BENCKISER GROUP PLC

 

2025 SHARE BUYBACK PROGRAMME

COMPLETION OF FIRST TRANCHE AND COMMENCEMENT OF SECOND TRANCHE

 

 

Reckitt Benckiser Group plc ("Reckitt" or the "Company") confirms the
successful completion of the first tranche of £250m (the "First Tranche") of
its 2025 £1 billion share buyback programme (the "Programme") announced on 24
July 2025.

 

Under the First Tranche, between 28 July 2025 and 21 October 2025, the Company
has purchased 4,445,840 ordinary shares of 10p each (the "Ordinary Shares") at
an average price of £56.23, and which have been cancelled.

 

Further to the announcement on 26 September 2025, the Company confirms that
the second tranche of the Programme (the "Second Tranche") to return a further
up to £250 million of capital to shareholders, will commence on 22 October
2025 and will end on or before 30 January 2026.  As previously announced, the
purpose of the Second Tranche is to reduce the share capital of the Company.
The Second Tranche will take place within the limitations of the authority
granted to the Board by shareholders at the Company's Annual General Meeting
on 8 May 2025. Pursuant to that authority, the maximum number of shares which
remain available for purchase under the Second Tranche is 63,954,160.

 

As previously announced, Reckitt has entered into an agreement with BNP
Paribas under which it has instructed BNP Paribas to manage the Second Tranche
of the Programme.  BNP Paribas will, acting as riskless principal, purchase
Ordinary Shares for an aggregate purchase price of no greater than £250
million and will simultaneously sell such Ordinary Shares on to the Company.
To the extent permitted by law, Ordinary Shares purchased under the Second
Tranche of the Programme will be held in treasury until completion of the
Second Tranche, at which time they will be cancelled.

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

CONTACT DETAILS:

 

Nick
Ashworth
            +44 (0)7408 812350

Investor Relations Director

 

Catheryn O'Rourke
 
+44 (0) 1753 217 800

General Counsel & Company Secretary

 

About Reckitt*:

 

We make the products people trust to care for the ones they love. We are home
to some of the world's best-loved consumer health and hygiene brands,
including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen,
Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By
creating innovative, science-backed solutions, we support people every day to
live healthier lives.

 

Reckitt exists to protect, heal and nurture in the pursuit of a cleaner,
healthier world. This commitment goes beyond the products we make. Through our
actions, we expand access to healthcare, education and economic opportunities.
We support the planet by reducing waste, conserving resources and driving
sustainable innovation.

 

We believe good health starts at home. With every action we take, we strive to
make our consumers' lives easier, cleaner and healthier, to strengthen
communities and to create a more sustainable future.

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZMZGNMFGKZM



            Copyright 2019 Regulatory News Service, all rights reserved